MiR-218 Inhibits Invasion and Metastasis of Gastric Cancer by Targeting the Robo1 Receptor

Jun Tie, Yanglin Pan, Lina Zhao, Kaichun Wu, Jie Liu, Shiren Sun, Xuegang Guo, Biaolu Wang, Yi Gang, Yongguo Zhang, Quanjiang Li, Taidong Qiao, Qingchuan Zhao, Yongzhan Nie, Daiming Fan

State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, X’An, Shaanxi, China

Abstract

MicroRNAs play key roles in tumor metastasis. Here, we describe the regulation and function of miR-218 in gastric cancer (GC) metastasis. miR-218 expression is decreased along with the expression of one of its host genes, Slit3 in metastatic GC. However, Robo1, one of several Slit receptors, is negatively regulated by miR-218, thus establishing a negative feedback loop. Decreased miR-218 levels eliminate Robo1 repression, which activates the Slit-Robo1 pathway through the interaction between Robo1 and Slit2, thus triggering tumor metastasis. The restoration of miR-218 suppresses Robo1 expression and inhibits tumor cell invasion and metastasis in vitro and in vivo. Taken together, our results describe a Slit-miR-218-Robo1 regulatory circuit whose dysregulation may contribute to GC metastasis. Targeting miR-218 may provide a strategy for blocking tumor metastasis.

Introduction

Advances in diagnostic and therapeutic approaches have led to excellent expectations for long-term survival for early gastric cancer (GC). However, the prognosis for advanced GC with extensive invasion and metastasis remains poor [1]. In order to metastasize, tumor cells must pass through a series of sequential and selective events, including detachment, migration, local invasion, angiogenesis, intravasation, survival in the circulatory system, extravasation, and regrowth in different organs. In the metastatic cascade, invasion of GC into the surrounding tissue is a crucial early step [2–4]. However, the mechanisms of invasion have not yet been fully elucidated.

A large number of microribonucleic acids (microRNAs or miRNAs) have been recently implicated in cancer metastasis [5], including miR-10b, miR-21, miR-126, miR-335, miR-573, miR-146, miR-520c, and miR-205 in breast cancer [6–11]; miR-224 and miR-21 in prostate cancer [12,13]; miR-29c in nasopharyngeal carcinomas [14]; miR-10a, miR-222, miR-125b, miR-7, and miR-452 in urothelial carcinomas [15]; miR-182 in melanoma [16]; miR-92b and miR-9-3* in brain tumors [17]; and miR-21 in colorectal cancer [18]. However, very few miRNAs known to be involved in GC metastasis have been reported. miRNAs are naturally occurring, short, non-coding RNA molecules that negatively regulate gene expression [19]. In mammals, mature miRNAs are generated from pri-miRNAs and pre-miRNAs via sequential processing by Drosa and Dicer and are found in many organisms. They consist of 21–24 nucleotides, integrate into RNA-inducing silencing complexes, and pair with the 3′ untranslated regions (3′-UTR) of specific target messenger RNAs (mRNAs) to suppress translation or induce degradation of the target mRNAs [20]. Emerging evidence has revealed that miRNAs play key roles in various biological processes, including cell differentiation, proliferation, apoptosis, stress resistance, fat metabolism, tumorigenesis, and metastasis [21–23]. A better understanding of the changes in miRNA expression during GC invasion may lead to a better understanding of GC development, as well as possible improvements in the diagnosis and treatment of advanced GC.

In the present study, we established high (MKN28-M and SGC7901-M) and low invasive cell sublines (MKN28-NM and SGC7901-NM) using a repetitive transwell assay in vitro. We then examined the global miRNA expression profile in each cell subline using a miRNA microarray to identify differentially expressed miRNAs related to human GC invasion. In total, 45 miRNAs were shown to be differentially expressed in invasive vs. non-invasive GC cells. Among these, miR-218, a significantly downregulated miRNA in highly invasive cells, was shown to be closely correlated with GC tumorigenesis and metastasis in patients. More recently, a decrease in miR-218 has been reported in several kinds of solid tumors, including prostate cancer, GC, lung cancer, and cervical carcinoma [24–27], but this decrease in miR-218 was simply screened out as being one of the dozens of potential miRNAs of interest in the cancers described above. No further studies have been performed to assess the significance of miR-218 in tumor metastasis. Here, we have found that decreased miR-218 expression was correlated with advanced clinical stage, lymph node metastasis, and poor prognosis in patients, and re-expression of miR-218 in metastatic cells was able to inhibit
migration, invasion, and metastasis formation both in vitro and in vivo. Using a bioinformatics search for miR-218 targets, we pinpointed the receptor Robo1 as miR-218’s functional target, and we confirmed that the interaction between miR-218 and Robo1 was crucial to GC cell motility by demonstrating that there was an inverse correlation between miR-218 and Robo1 in GC cell lines as well as in GC patients. Furthermore, we discovered an intriguing negative feedback loop involving Slit, miR-218, and Robo1, in which miR-218 can be derived from either of two genes located in the introns of two distinct members of the Slit protein family. In addition, members of this family are ligands of the Robo1 receptor. We demonstrated that expression of the two miRNA precursor genes (miR-218-1 and miR-218-2) correlated with expression of the host genes (Slit2 and Slit3, respectively) and that the mature miR-218 was mainly derived from the miR-218-2 precursor, with a concomitant reduction of host Slit3 but not of Slit2 in metastatic GC cells. Thus, upregulation of Robo1 in response to the decrease in miR-218 induced a reactive upregulation of the Slit-Robo1 pathway through its interaction with Slit2, thus facilitating tumor cell migration and metastasis. Our findings not only provide new insights into the metastatic mechanisms in GC but also provide evidence for a novel miRNA-mediated regulatory mode of receptor signaling.

Results

Establishment and characterization of cell sublines with different invasive and metastatic potentials

To establish the GC metastasis models, we created invasive and non-invasive cell sublines from the human GC cell lines SGC7901 and MKN28 using the repeated transwell approach (Figure 1A, see Materials and Methods). Briefly, a repetitive invasion assay was performed, and those cells that failed to invade the membranes and cells that had the ability to migrate through the collagen-coated membrane in all selection rounds were separated. After ten rounds of selection, we obtained invasive (MKN28-M and SGC7901-M) and non-invasive cell sublines (MKN28-NM and SGC7901-NM). The metastatic properties of each cell subline were then characterized in vitro and in vivo. As shown in Figure 1B and 1C, migration ability of MKN28-M cells was approximately 4-fold greater than that of MKN28-NM cells. Likewise, the invasive potential was about 5-fold greater for MKN28-M cells as compared to MKN28-NM cells. In the in vivo studies, tumor cell metastasis was observed in nude mice. As shown in Figure 1D and 1E, almost no metastatic GC cells were detected in the lungs or livers of nude mice at 10 weeks after injection of MKN28-NM cells, whereas most of the mice injected with MKN28-M cells displayed obvious lung or liver metastases. Similar results were also observed for SGC7901-M and SGC7901-NM cells (data not shown). No significant differences in cell proliferation or cell-cycle distribution were observed among these cell sublines (Text S1, Figures S1 and S2).

Identification of metastasis-related miRNAs by array-based hybridization

To identify miRNAs potentially involved in GC invasion, we examined global miRNA expression in each cell subline using the microRNA array (v.10.0, Exiqon, Vedbaek, Denmark), which consists of 847 capture probes for mature human miRNAs. The microarray results revealed that the expression of 124 miRNAs significantly differed between the highly invasive variant MKN28-M and the non-invasive cell subline MKN28-NM. Of these, 83 were upregulated and 41 were downregulated. Compared with SGC7901-NM, 62 miRNAs were differentially expressed in the SGC7901-M cell subline, including 47 downregulated and 15 upregulated miRNAs. In total, 11 miRNAs were found to be upregulated and 34 miRNAs were downregulated in both MKN28-M and SGC7901-M cells compared with those in the corresponding non-invasive sublines (Table S1).

Of the 45 differentially regulated miRNAs, miR-218 was one of those that displayed significantly differential expression. miR-218 has been reported to be downregulated in cervical cancer [25],...
GC [26], lung cancer [27] and prostate cancer [28], indicating possible involvement in both oncogenic transformation and tumor metastasis. However, miRNA-218 was only one of the many potential miRNAs of interest in cancers. In this work, miR-218 has been investigated in much greater detail. To validate the microarray results, we assessed miR-218 expression in the GC cell sublines previously mentioned and in the immortal gastric epithelial cell line GES using qRT–PCR [29]. miR-218 expression was significantly decreased in MKN28-M and SGC7901-M cells and was lower in all four GC cell sublines compared to immortalized human gastric epithelial GES cells (Figure 2A). Furthermore, we compared miR-218 expression in the primary GC tumor vs. the metastatic lymph nodes in 10 patients with stage III/IV GC using qRT–PCR. As shown in Figure 2B, mature miR-218 levels were significantly decreased in 7 out of 10 metastatic lymph nodes, indicating that miR-218 may play a causal role in GC metastasis.

Figure 2. Validation of miR-218 expression in metastatic GC cells. The expression of miR-218 was investigated by qRT-PCR. (A) Each bar represents the relative fold change compared to GES cell lines. (B) Bars represent relative fold changes between primary GC and metastatic lymph nodes from the same patient. Each sample was analyzed in triplicate and was normalized to U6. Fold change was calculated by $2^{-\Delta\Delta Ct}$. The results were consistent with the microarray data.

doi:10.1371/journal.pgen.1000879.g002

Decreased miR-218 expression in GC was associated with advanced clinical stage, lymph node metastasis, and poor patient prognosis

To determine the potential clinicopathological implications of altered miR-218 expression, we investigated the expression levels of miR-218 in 40 GC tissues (T) and non-tumor mucosa (N) by qRT–PCR. The term -ΔΔCt was used to describe the expression level of miR-218. Consistent with the above data, the results verified that the miR-218 expression level in GC (-13.81±0.15, mean ± SE) tissues was significantly lower than that in non-neoplastic mucosa (-13.07±0.24, mean ± SE) ($P=0.0036$, $t=10.62$, paired $t$-test) (Figure 3A). Correlations between the miR-218 expression level and clinicopathologic characteristics of GC are summarized in Table 1. Statistically significant associations between the miR-218 expression level and clinical stage and between the miR-218 expression level and GC metastasis were observed in this study. The median expression of miR-218 was −14.25±0.17 in the 22 cases with advanced stage (stage III and IV) disease, whereas the median expression was −13.27±0.20 ($P=0.0010$, Mann-Whitney test) in the 18 cases with early-stage (stages I and II) disease. In the 29 cases of GC with lymph node metastasis, the median expression of miR-218 was −14.09±0.16, which was significantly lower than the median expression ($-13.07\pm0.24$) in the 11 non-metastatic GC cases ($P=0.0036$). The expression of miR-218 in GC patients did not correlate with age, gender, tumor size, or cell differentiation. Moreover, we examined whether the level of miR-218 expression was associated with survival in patients with GC. Patients were subsequently divided into low expression ($n=20$) and high expression groups ($n=20$) based on miR-218 levels greater or less than the mean ($-13.81$) (Figure 3B). Kaplan–Meier survival analyses revealed that patients whose primary tumors displayed low expression of miR-218 had significantly poorer survival than those with high expression ($P=0.0012$).

Figure 3. miR-218 expression in clinical GC specimens. (A) miR-218 was differentially expressed between GC and the corresponding non-neoplastic mucosa (N). The term -ΔΔCt was used to describe the expression level of miR-218 ($-\Delta\Delta Ct = C_{U6} - C_{miR-218}$). A significant difference was detected in the mean value of miR-218 expression between these two groups ($P<0.0001$, $t=10.62$, paired $t$-test). (B) The same GC samples as in (A) were divided into two groups according to the mean expression of miR-218 (mean, −13.81). Cases with levels of miR-218 below the mean were miR-218 low expressers ($n=20$), and those with levels of miR-218 above the mean were miR-218 high expressers ($n=20$). (C) Kaplan–Meier survival curve and log-rank test for GC patients between high and low miR-218 expressers. miR-218 expression demonstrated a significant relationship with patient survival (log-rank, $P=0.0012$).

doi:10.1371/journal.pgen.1000879.g003
miR-218 had a shorter median survival time. The three-year survival rate of patients with low miR-218 expression was 30%, which was significantly lower than the survival rate in patients with high miR-218 expression (65%; $P = 0.0012$, log-rank test; Figure 3C).

Ectopic expression of miR-218 inhibited tumor cell invasion and metastasis

To study the role of miR-218 in GC metastasis, MKN28-M cells were transfected with pGenesil-1-miR-218 or a control vector expressing a nonspecific miRNA, cel-miR-67, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The cells were then selected with 400 mg/L G418 to generate MKN28-M-miR-218 and MKN28-M-miR-control stable cells. We found that ectopic expression of miR-218 resulted in an approximately three-fold reduction in migration and invasiveness. To determine whether the loss of miR-218 would promote the migration or invasion of cancer cells, we silenced miR-218 with an antisense oligonucleotide inhibitor in the MKN28-NM cell line, resulting in a three- to four-fold increase in cell migration and invasiveness (Figure 4A and 4B). To test if inhibition of tumor invasion by miR-218 is caused by impairing the invasive ability of tumor cells, we excluded the effect of miR-218 on the proliferation and cell cycle distribution of gastric cancer cells. Over-expression of miR-218 did not affect the proliferation and the cell cycle distribution of MKN28-M cells in vitro (Figure S5A and S5D). To further investigate the inhibition of in vivo tumor metastasis by miR-218, we implanted MKN28-M-miR-218 cells that were stably expressing miR-218 or control cells into nude mice through the lateral tail vein. Lung and liver metastasis of GC was apparent in mice injected with MKN28-M-miR-control cells. In contrast, few metastatic tumors were detected in mice injected with MKN28-M-miR-218 cells (Figure 4C). Furthermore, we simultaneously observed the growth of the primary tumors and the incidence of distant metastasis in mice injected subcutaneously with MKN28-M-miR-218 cells or control cells. The results showed lung or liver metastasis was apparent in 3 out of 10 mice injected with MKN28-M-miR-control cells; in stark contrast, no metastasis were found in mice injected with MKN28-M-miR-218 cells (Figure S5E). These results are consistent with data obtained from tail vein assays that assess cancer metastasis and indicate that miR-218 has the ability to suppress metastasis without affecting cell proliferation.

Robo1 was a direct functional target of miR-218 in GC metastasis

To assess how a low level of miR-218 expression contributes to the invasion and metastasis of GC, we searched for the potential

| Variable                        | Number of cases | Median expression of miR-218 (range) | P value |
|---------------------------------|-----------------|-------------------------------------|---------|
| Age (years)                     |                 |                                     |         |
| ≥60                             | 16              | 40%                                 | 0.85    |
| <60                             | 24              | 60%                                 |         |
| Gender                          |                 |                                     |         |
| Male                            | 30              | 75%                                 | 0.43    |
| Female                          | 10              | 25%                                 |         |
| Tumor size                      |                 |                                     |         |
| ≥5                              | 26              | 65%                                 | 0.36    |
| <5                              | 14              | 35%                                 |         |
| Degree of differentiation       |                 |                                     |         |
| well and moderately differentiated | 18         | 45%                                 | 0.7649  |
| poorly differentiated            | 22              | 55%                                 |         |
| TNM stage                       |                 |                                     |         |
| Stage I/II                      | 18              | 45%                                 | 0.0010  |
| Stage III/IV                    | 22              | 55%                                 | 0.17    |
| Lymph node status               |                 |                                     |         |
| Metastasis                      | 29              | 72.5%                               | 0.0036  |
| No metastasis                   | 11              | 27.5%                               | 0.24    |

Table 1. The relationship between clinicopathological parameters and miR-218 expression in primary gastric adenocarcinoma.

![Figure 4](https://example.com)
MiR-218 Inhibits Invasion and Metastasis

regulatory targets of miR-218 using prediction tools, including miRanda, PicTar, and TargetScan. Although hundreds of different targets were predicted, those genes involved in migration or invasion may be the relevant targets with respect to the biological functions of miR-218. We then performed a functional classification of the predicted targets using the DAVID program (http://david.abcc.ncifcrf.gov/). Of these genes, Robo1 is regarded as a proto-oncogene and harbors migration-promoting activity [30–33]. Mertsch et al. demonstrated that Robo1 facilitates glioma cell migration mediated by Slit2 [36]. Schmid et al. found that breast tumor cell migration is induced by the Slit2-Robo1 interaction in vitro [37]. These findings suggest that Robo1 may be a target for miR-218. To further test our hypothesis, we analyzed the expression of miR-218 and Robo1 in GES and in non-invasive (MKN28-NM and SGC7901-NM) and invasive (MKN29-M and SGC7901-M) GC cells. The results showed a negative correlation between the levels of miR-218 and Robo1 mRNA in these cells (Figure S3A). Furthermore, we observed that Robo1 mRNA (Figure S3B) and protein (Figure S3B) levels decreased when miR-218 was expressed by pGenesil-1-miR-218 in MKN28-M cells (Figure S3B). The reverse was observed for Robo1 expression when miR-218 was knocked down in MKN28-NM cells (Figure 5C1 and Figure 5C2). The inverse relationship between miR-218 and Robo1 expression was further confirmed by immunohistochemistry (Text S1) in 40 cases of gastric cancer, in matched adjacent normal tissues that were also used in clinicopathological studies, and in 29 matched metastases. The results show that Robo1 was upregulated in GC, especially in metastatic GC (Figure S4), in which miR-218 has a relatively low expression.

To obtain further direct evidence that Robo1 is a target of miR-218, we investigated the binding site of miR-218 in the 3’-UTR of Robo1 mRNA (Figure 5A). We constructed a luciferase reporter (Luc-Robo1) in which the nucleotides of the Robo1 3’-UTR complementary to miR-218 (nt 971–978) were inserted into the pMIR-REPORT miRNA expression reporter vector [38]. Correspondingly, we also generated both a mutant reporter (Luc-Robo1-mu), in which the first six nucleotides in the miR-218 seed-region complementary sites were deleted, and a control reporter, which contained a non-related fragment of cDNA (Luc-Ctrl). miR-218-expression plasmids were co-transfected with Luc-Robo1, Luc-Robo1-mu, or Luc-Ctrl into MKN28-M cells. The assays showed that the luciferase activity in the Luc-Robo1-transfected cells was significantly decreased compared to the luciferase activity in the mutant and negative control cells (P<0.05), suggesting that miR-218 reduced the luciferase activity of Luc-Robo1 but had no effect on Luc-Robo1-mu (Figure 5D). Therefore, we concluded that the inserted fragment of Robo1 (nt 971–978) was the target of miR-218.

Robo1 has been shown to be over-expressed in cancer cells and is known to promote tumor angiogenesis and metastasis via an interaction with Slit [39,40]. To test whether Robo1 is functionally regulated by miR-218, we generated a Robo1 expression construct containing only a fragment of the predicted miR-218 binding site and Robo1 mutant expression vector entirely lacking the 3’-UTR. We also made the Robo1 siRNA. MKN28-M-miR-218 cells, which stably expressed miR-218 ectopically, were transiently transfected with the Robo1 construct or the mutant construct (with no miR-218 binding site), and MKN28-M cells were transfected with Robo1 siRNA or a negative control siRNA. MKN28-M-miR-218 cells transfected with the Robo1 mutant construct showed a 3.8-fold increase in invasion ability compared to cells transfected with the Robo1 construct. These results indicate that introduction of mutant Robo1 cDNA that lacked the miR-218 binding site into the miR-218-overexpressing cells reversed the effect of miR-218-mediated suppression of cell invasion. However, the effect of Robo1 was repressed by miR-218 in the presence of the Robo1 3’-UTR containing the miR-218 binding sites. Knockdown of Robo1 by siRNA in MKN28-M cells inhibited cell invasion, which fell to levels similar to those observed after transfection with the miR-218-expressing vector (Figure 5E and 5F). These observations suggest that miR-218 directly suppresses Robo1-mediated cell invasion.
Slit2, but not Slit3, can interact with Robo1, enriched by the absence of miR-218, to promote GC invasion.

Two types of miRNAs exist: intergenic and intronic. The former are located in non-coding regions between genes, and their corresponding pri-miRNAs are generally transcribed from their own promoters by RNA polymerase II. The latter are located within the introns of host genes, and their biogenesis is controlled by the host gene promoters [41,42]. miR-218 is an intronic miRNA. Two genes code for mature miR-218, miR-218-1 and miR-218-2, which are located within intron 15 of Slit2 and intron 14 of Slit3, respectively (Figure 6A). The intronic location of the two miR-218 genes prompted us to ask whether miR-218-1 and miR-218-2 are transcribed together with their host gene mRNAs.

Expression patterns of Slit2 with miR-218-1 (B) and Slit3 with miR-218-2 (C) exhibited a significant positive correlation, as did mature miR-218 with the miR-218-2 precursor (D), but not with miR-218-1 (E), in GC. A significant differential gene expression pattern was detected between normal and tumor samples with regard to Slit3 (P<0.0001, paired Student’s t-test, Figure 6F), but not Slit2 (P=0.0772, Figure 6G). Using relative quantification methods, the results were expressed as −ΔCt. The left and right lines of (F,G) represent the mean values for the normal and tumor groups, respectively.

doi:10.1371/journal.pgen.1000879.g006

To test this hypothesis, we used qRT-PCR to examine the expression of the miR-218-1 precursor, the miR-218-2 precursor, mature miR-218, Slit2 mRNA, and Slit3 mRNA in the GC tissues used in the survival analysis. Statistical analysis of the correlation coefficient of the qRT-PCR results revealed a significant positive correlation between the levels of Slit2 mRNA and miR-218-1 and between the levels of Slit3 mRNA and miR-218-2 (Figure 6B and 6C). These results indicate that the miR-218 coding genes, miR-218-1 and miR-218-2, are transcribed together with their host genes, Slit2 and Slit3, respectively. A significant positive correlation between the levels of miR-218-1 and miR-218-2 (Figure 6D) was seen in GC; however, no such correlation was seen between the levels of miR-218-1 and miR-218-2 (Figure 6E).

These results indicate that downregulation of miR-218 in GC is promoted by a decrease in miR-218-2, but not in miR-218-1. Consistent with this conclusion, Slit3 expression was significantly reduced in GC (−22.43±0.21, mean ± SE) compared to normal gastric tissue (−20.79±0.23, mean ± SE), (P<0.0001, t=7.67, paired t-test) (Figure 6F), whereas Slit2 expression was not significantly different (P=0.0772, paired t-test) (Figure 6G). In summary, our experimental results suggest that significant upregulation of the Robo1 gene in response to removal of miR-218 may induce a subsequent upregulation of the Slit-Robo1 pathway through its interaction with Slit2, facilitating tumor cell migration and invasion.

**Discussion**

To study a disease, it is vital to construct an ideal model. In the present study, we isolated invasive and non-invasive cell subpopulations from established human GC cell lines using the repeated transwell approach, which has been successfully applied in many studies investigating tumor metastasis [43–48]. The results of metastatic examination in vitro and in vivo showed that the established cell sublines had distinct invasive and metastatic capabilities. Here, we screened not only cell sublines derived from GC cell lines with high-invasive potential, but also those with low-invasive potential. With the exception of their metastatic abilities, the selected cell sublines were both quite similar, since they share the same genetic background. Since the major difference between the two types of sublines is metastatic capability, the genes that differ between them should correlate well with metastasis. Moreover, our method is able to distinguish invasion stages from metastasis and enables the study of specific steps in metastasis, which cannot be assessed in the live-animal model.

Recently, miRNAs have been reported to promote [49,50] or suppress [51–54] tumor metastasis, providing a new perspective on the metastatic process. Nonetheless, the role of miRNAs in GC metastasis is lacking. In this report, we explored and obtained for the first time 45 metastasis-related miRNAs in GC based on a well-established metastasis cell model. The finding that miR-218 was downregulated in metastatic GC is intriguing, as decreased miR-218 levels have been reported in several types of solid tumors [24–27,55], indicating that the loss of miR-218 may be a common event in tumorigenesis. In the present study, we focused on the effect of miR-218 on GC metastasis and demonstrated that miR-218 acts as a tumor suppressor in GC metastasis. Restoration of miR-218 reduced cell migration and invasion in vitro and tumor metastasis in vivo. To obtain stable cell lines that over-expressed miR-218, we transfected MKN28-M cells with miR-218 plasmids and screened by G418. We selected twelve cell colonies in the miR-218-transfected group and found 10 out of 12 colonies exhibited remarkably uniform, stable and high-level expression of miR-218. Furthermore, three randomly chosen monoclonal cell
lines exhibited similar reduction in invasive ability. However, plasmid transfection strategies often result in lower integration efficiency compared to viral expression leading to the possibility of stochastic selection of rare functionally heterogeneous variants from the initial bulk population. Therefore the future use of viral expression systems should create a more unbiased starting population to test our hypothesis.

As part of our research on how the loss of miR-218 affects GC metastasis, we demonstrated that Robo1 was a critical downstream target of miR-218. It is known that Robo is an axon guidance receptor for Slit and is conserved in animals ranging from fruit flies to mammals. In mammals, three Slit (Slit1–3) and four Robo (Robo1–4) genes have been described [36,57]. The Slit–Robo interactions convey signals mediates repulsive cues on axons and growth cones during neural development and participate in T cell and monocyte chemotaxis [58–64]. As for other developmental pathways, aberrant expression of the Slit-Robo genes has been observed in a variety of tumor types [65–68]. For instance, in breast carcinoma tissue samples, Robo1 has been shown to be over-expressed, and it has been demonstrated to induce migration of breast cancer cell lines [37]. Slit2-Robo signaling facilitates glioma cell migration [36] and is involved in angiogenesis by increasing microvessel density and tumor mass in a tumor xenograft model [30]. Wang et al. demonstrated that the over-expression of Robo1 in new blood vessels in tumors induces cancer neovascularization and growth via an interaction between Robo1 and its ligand, Slit2. They also identified phosphoinositide-3-kinase (PI-3K) as a downstream effector of Slit2/Robo1 signaling. This suggests that there exists a Slit-Robo1–PI-3K cascade that could lead to the generation of phosphoinositol-3,4,5-triphosphate and the subsequent activation of small GTPases that mediate cell movement and remodeling of the actin cytoskeleton [30,35]. In contrast, other studies have argued that the downregulation of Robo1 caused by deletions or epigenetic modifications may play a role in tumor progression [69–73]. We propose that a tissue-specific expression pattern exists for the Slit-Robo genes.

In the current study, we found that Robo1 was often expressed at high levels in invasive cells and at low levels in non-invasive cells, whereas miR-218 displayed the opposite expression pattern. When we transfected the miR-218-expression vector and inhibiting oligonucleotides into MKN28-M and MKN28-NM cells, respectively, an inverse expression pattern was observed between miR-218 and Robo1, that is, if miR-218 expression was high, Robo1 expression was low and vice versa. This result was further confirmed in clinical samples and in luciferase activity assays. We also noticed that induction of expression of Robo1 by the Robo1 mutant construct without the miR-218 binding site could reverse miR-218-mediated suppression of tumor cell invasion. In contrast, knockdown of Robo1 gene expression by RNAi had an effect on reducing tumor cell invasion similar to that of the restoration of miR-218, although Robo1 knockdown alone demonstrated a weak effect. This could be because Robo1 is not the only target of miR-218 that is relevant to tumor metastasis. These findings indicate that the invasion suppression effect of miR-218 is at least partly mediated through a decrease in Robo1 expression. This is also the first study to show that the tumor-associated gene Robo1 is negatively regulated by miR-218 via a specific target site (nt 971–978) within the 3'-UTR. The Robo1 receptor is crucial for the response to extracellular signals and cellular phenotypic changes; therefore, tight regulation of the Robo1 receptor by miR-218 may facilitate more robust signal transduction. Anti-Robo1 monoclonal antibody has been reported to be an effective treatment for Robo1-expressing cancers [30,33]. In the present study, we found a new inhibitor of Robo1, miR-218, that may potentially be used to treat some types of cancer.

As mentioned above, Slit1, Slit2, and Slit3 comprise the Slit family of proteins. Although the genes overlap, their expression patterns and functions are distinct. The former two proteins are known to be involved in axon guidance and cell migration [37,74], while Slit3 is involved in the development of organs and organ systems, including the diaphragm and the kidney [73]. In agreement with these data, we found that Slit2, but not Slit3, interacted with Robo1 to promote GC invasion.

In addition, we demonstrated that the miR-218 coding genes were located in and transcribed together with Slit genes, which were Robo1 ligands, thus creating a negative feedback loop that regulates Slit/Robo1 signaling. Sainel Barik demonstrated that an intrinsic miRNA, miR-338, silenced genes that are functionally antagonistic to its host gene product, thus creating a positive feedback loop that assists in the physiological role of the host gene [76]. However, a miRNA hosted in a ligand gene that simultaneously targets its corresponding receptor gene has never been reported. We have identified a negative regulatory loop involving the ligand (host gene), the intronic miRNA, and the receptor, in which the miRNA is co-transcribed with the ligand while receptor expression is repressed. The associations among ligand/receptor and intrinsic miRNA indicate that the early steps in the information flow may have built-in controls to limit excess signal propagation, which include a negative feedback loop to preserve homeostasis. This regulatory model, which is based on intrinsic miRNAs, is a novel mechanism of regulation in receptor signaling systems. Even though the full regulatory circuitry of miR-218 has yet to be completely elucidated, our study revealed a potential negative feedback pattern in which a miRNA was co-transcribed with the Slits ligand and repressed Robo1 receptor expression. This study not only provides new insights into the metastatic mechanism of GC but also generates a set of testable hypotheses that are helpful for understanding the miRNA-mediated regulation of cellular ligand/receptor interactions.

In conclusion, we have identified miRNAs that are aberrantly expressed in invasive GC cells compared with non-invasive GC cells. Here we have showed that when significantly downregulated, miR-218 promoted GC cell invasion and metastasis, at least in part via induction of Robo1. This result indicates that restoration of miR-218 may be a rational therapeutic strategy for the treatment of GC in the future. It remains to be investigated whether the other differentially expressed miRNAs found in this study also participate in GC metastasis. Importantly, our findings have implications for describing new mechanisms for miRNA-mediated regulation of receptor signaling.

Materials and Methods

Ethics statement

All experimental procedures were approved by the Institutional Review Board of the Fourth Military Medical University. Written informed consent was obtained for all patient samples. Animal experiments were performed with the approval of the Institutional Committee for Animal Research and in conformity with national guidelines for the care and use of laboratory animals.

Cell culture

The human GC cell lines MKN28 and SGC7901 were routinely maintained in RPMI-1640 medium (GIBCO, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 100 U/ml of penicillin sodium, and 100 μg/ml of streptomycin sulfate at 37°C in a humidified air atmosphere containing 5% carbon
dioxide. Throughout the experiment, cells were used in the logarithmic phase of growth.

**Isolation of invasive and non-invasive cell sublines using transwell chambers**

Six-well polycarbonate transwell membrane inserts with 8-μm pores (Corning, USA) were used to isolate cell sublines with different levels of invasiveness from the cultured MKN28 cell line. First, cells that were serum-starved for 24 h were suspended in serum-free RPMI-1640 to a final cell density of $5 \times 10^5$ cells/mL. A 1 mL cell suspension was seeded into the top chamber, which was coated with 200 mg/mL of Matrigel (BD Biosciences, San Jose, CA, USA), and the lower well beneath the polycarbonate membranes was filled with 2.5 mL RPMI-1640 medium supplemented with 20% bovine serum to create a chemotactic gradient to stimulate penetration of the cells. Following incubation for 24 h at 37°C, the invasive cells on the underside of the membrane and the non-invasive cells on the top of the membrane were harvested aseptically and were expanded for selection. Via ten-round selection, the cell subline that failed to invade through the membranes in all selection rounds was designated as MKN28-NM, and the subline that was able to migrate through the membranes was designated as MKN28-M. We also obtained two cell sublines, SGC7901-M and SGC7901-NM, derived from the SGC7901 GC cell line, using the same method (Figure 1).

**In vitro migration and invasion assays**

A 24-well transwell plate (8-μm pore size, Corning, USA) was used to measure each cell line’s migratory and invasive ability. For transwell migration assays, 2.5 $\times 10^5$ cells were plated in the top chamber lined with a non-coated membrane. For invasion assays, transwells were coated with 200 mg/mL of Matrigel and dried overnight under sterile conditions. Then, 5 $\times 10^4$ cells were plated in the top chamber. In both assays, cells were suspended in medium without serum or growth factors, and medium supplemented with serum was used as a chemoattractant in the lower chamber. After incubation at 37°C for 24 h, the top chambers were wiped with cotton wool to remove the non-migratory or non-invasive cells. The invading cells on the underside of the membrane were fixed in 100% methanol for 10 min, air-dried, stained in 0.1% crystal violet, and counted under a microscope. The mean of triplicate assays for each experimental condition was used.

**Experimental metastasis**

To produce experimental metastasis, cells were washed and resuspended in PBS. Five-week-old BALB/c-nu/nu nude mice obtained from the Shanghai Laboratory Animal Center of China were injected into the lateral tail vein, and the animals were maintained in a sterile animal facility. Each tumor cell subline was injected into ten mice. After ten weeks, the mice were killed, and the lungs and liver were examined for metastases. Tumor tissues derived from various organs were dissected and examined histologically. The experiments were repeated two to three times.

**miRNA microarrays**

Total RNA was extracted from each cell subline using the miRVana miRNA Isolation Kit (Ambion Inc., Austin, TX, USA) according to the manufacturer’s instructions. The purity and quantity of the isolated RNAs were assessed using 1% formaldehyde-agarose gel electrophoresis and spectrophotometry (Bio-Rad, Hercules, CA, USA). We then submitted the samples to KangChen-Biotech (Shanghai, China) for array hybridization on a miRCURY LNA microRNA array (v.10.0, Exiqon, Vedbaek, Denmark). Each microarray chip was hybridized with a single sample labeled with either Cy3 or Cy5. Background subtraction and normalization were performed. We selected miRNAs whose expression levels between invasive cell sublines and non-invasive cell sublines differed by at least 1.5-fold.

**Clinical samples**

Forty patients (30 males and 10 females) who had undergone gastrectomy with lymph node dissection for gastric carcinoma at Xijing Hospital between March and September of 2003 were included in the study (Table S2). The patients ranged in age from 26 to 77 years (median 54.13 years). None of the patients received preoperative chemotherapy. The resected specimens were histologically examined by H&E staining. The primary tumor tissues and corresponding non-tumor mucosa and lymph nodes were collected from each patient immediately after surgical removal and snap-frozen in liquid nitrogen until further use. Total RNA from the frozen tissues was isolated with Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

**Quantitative real-time RT–PCR (qRT–PCR)**

Total RNA was extracted with suitable reagents. The TaqMan stem-loop RT–PCR method was used to assess the expression of miRNAs with kits from Applied Biosystems (Foster City, CA, USA). SYBR green real-time RT–PCR was performed to detect Sli2, Sli3, and Robol. All RT–PCR experiments were performed on a Chromo4 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The primers for miR-218 and its precursors were obtained from Applied Biosystems (Foster City, California, USA) and Eurogentec North America, Inc (Flintkote Avenue, San Diego, California, USA); respectively. The primers for Sli2, Sli3, and Robol were designed to produce amplicons that were 76-150 bp in length and with an annealing temperature of approximately 60°C using Primer Premier v5.0 Software. Data are presented as fold differences relative to either 18S for Sli2, Sli3, and Robol or U6 for miRNA based on calculations of $2^{-\Delta\Delta Ct}$. All primer sequences in this study are listed in Table S3.

**Construct design and cell transfections**

**miR-218-expressing vector.** The precursor sequence of miR-218 (110 bp, MI0000295) generated by annealing and primer extension with miR-218-precursor-F and miR-218-precursor-R (Table S3) was digested with BamHI and HindIII and cloned into the BamHI-HindIII fragment of the pGenesil-1 vector. A construct including the nonspecific miRNA cel-miR-67 (99 bp, MI0000038) was used as a negative control.

**Luc-Robol vector.** The Robol 3’-UTR containing the predicted miR-218 binding site was amplified by RT-PCR from the total RNA of cultured MKN28 cells and was cloned into the pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA). The pCR2.1-TOPO-Robo1 3’-UTR construct was digested with SpeI and HindIII. The resulting fragment was subcloned into the SpeI and HindIII sites of the pMIR-REPORT miRNA expression reporter vector (Applied Biosystems). The first six nucleotides complementary to the miR-218 seed-region were deleted from the mutant constructs using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s protocol.

**Robol-expressing vector with or without miR-218 binding sites.** Full-length Robol cDNA that entirely lacks the 3’-UTR (Clone ID: 9057080) was purchased from Open Biosystems (USA) and was subcloned into the eukaryotic expression vector

---

**MiR-218 Inhibits Invasion and Metastasis**

**Plasmodi...**
pcDNA3.1(+) to generate the Robo1 mutant expression vector. A Robo1-expressing vector was constructed by inserting the fragment of the predicted miR-218 binding site into the Robo1 mutant expression vector. Robo1 siRNA and negative control oligonucleotides were purchased from GenePharma (Shanghai, China).

**Cell transfections.** MKN28-M cells were transfected with the miR-218-expressing vector or the control vector expressing a nonspecific miRNA, cel-mir-67, using Lipofectamine 2000 (Invitrogen), and were selected with 400 μg/L G418 to generate two stable monoclonal cell lines (a miR-218 stable cell line, MKN28-M-miR-218, and a control stable cell line, MKN28-M-miR-control). The oligonucleotides comprising the miR-218 inhibitor and the mismatched sequence negative control were purchased from Ambion Inc. and were transfected into MKN28-NM cells using Oligofectamine (Invitrogen). The Robo1-expressing vector with or without the miR-218 binding sites was transfected into MKN28-M-miR-218 cells, and Robo1 siRNA was transfected into MKN28-M-miR-control cells.

**Luciferase assay.** The pMIR-REPORT β-galactosidase control vector and Luc-Robo1, Luc-Robo1-mu, or Luc-control were co-transfected into MKN28-M-miR-218 cells. Lysates were prepared at 48 h post-transfection. Luciferase activity was measured using the Dual-Light luminescent reporter gene assay (Applied Biosystems). All measurements were normalized to β-galactosidase activities to correct for variations in transfection efficiencies and for non-miR-218-specific effects of miRNA transfection on enzymatic activity.

**Western blot.** Cellular proteins were extracted and separated in SDS-PAGE gels, and western blot analyses were performed according to standard procedures. Western blotting of β-actin on the same membrane was used as a loading control. The antibodies used were anti-Robo1 (SC-25672) and anti-β-actin (sc-47778), both from Santa Cruz Biotechnology (CA, USA).

**Statistical analyses.** All data are presented as means ± SE and were analyzed using Prism 5.0 software (GraphPad). The significance of the observed differences was determined with the Student’s t-test or the χ2 test. The relationships among the miR-218-1 precursor, the miR-218-2 precursor, mature miR-218, Sht2 mRNA, and Slt3 mRNA were analyzed by correlation coefficients and linear regression analysis. *P* < 0.05 was considered statistically significant. **P** < 0.01.

**Supporting Information**

**Figure S1** No significant difference in the proliferation rate was observed in the three cell sublines. (A) Proliferation rates of the cell sublines were detected by the MTT assay. (B) Tumor volume growth curves for each cell subline are shown. Tumor sizes were measured using calipers. Tumor volume was calculated using the formula (length × width²)/2. (C) On day 37, all tumors were collected to measure tumor weights. (D) Photos of tumors 37 days after injection with MKN28, MKN28-NM, or MKN28-M cells. Found at: doi:10.1371/journal.pgen.1000879.s001 (6.14 MB TIF)

**Figure S2** Cell-cycle analysis of three established cell sublines. (A) Representative flow cytometry results for each cell subline. (B) Cell-cycle distribution. (C) Median tumor weight at day 72. Data are presented as mean ± standard error. (D) Cell cycle distribution. Magnification, 200×.

**Table S1** Differentially expressed miRNAs in highly invasive GC cells versus non-invasive GC cells.

**Table S2** Clinicopathologic features in 40 tumor samples.

**Table S3** Primer sequences used in the study.

**Acknowledgments**

We thank Zhao Yiling, Department of Pathology, Xijing Hospital, for histological assessment; Liang Shuhui for help with the animal experiment; Li Zeng, Cheng Ying, and Shen Xin for collecting the clinical samples; and He Biyun for assistance with statistical data analysis. We also thank Derek M. Erion for revising the manuscript.

**Author Contributions**

Conceived and designed the experiments: JT YP KW JL YN DF. Performed the experiments: JT YP LZ SS BW YG YZ TQ. Analyzed the data: JT QL DF. Contributed reagents/materials/analysis tools: XG QZ DF. Wrote the paper: JT.
20. Lai EC (2002) Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363–364.

21. Lu JG, Gertz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834–838.

22. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancerogenesis. Proc Natl Acad Sci U S A 103: 2257–2262.

23. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, et al. (2008) Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinomas. Oncogene 27: 2572–2582.

24. Petrocca F, Viscione R, Onelli MR, Shah MH, Nicolis MS, et al. (2008) EZH2-regulated microRNAs impair G1/T/G2a-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 12: 272–286.

25. Yanahara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.

26. Leite KR, Sousa-Cavanez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, et al. (2009) Change in expression of miR-101, miR-100, and miR-218 from high grade localized prostate cancer to prostate cancer. Urol Oncol. 27: 2257–2261.

27. de Haas G, Yang Y, Ding YW, Liu W, Shen QY, et al. (2006) Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 55: 797–801.

28. Wang B, Xiao Y, Ding B-B, Zhang N, Yuan X-B, et al. (2003) Induction of tumor angiogenesis by Sm-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Res 63: 14–19.

29. Sulting H, Heal P, Tahtis K, Stewart LM, Bicknell R (2005) Soluble Robo receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J 19: 121–123.

30. Grome J, Doebler O, Loddenkemper C, Holz B, Buhr HJ, et al. (2006) Robo1/Robo2 differential expression of angiogenic markers in colorectal cancer. Oncol Rep 15: 1437–1443.

31. Ito H, Funahashi S, Yamauchi N, Shibahara J, Midorikawa Y, et al. (2006) Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin Cancer Res 12: 3257–3264.

32. Lee CH, Fang CY, Shu JH, Chang Y, Takada K, et al. (2008) Amplification on chromosome 3 contains oncogenes induced by recurrent exposure to 12-O-tetradecanoylphorbol-13-acetate and sodium selenite in Balb/c 3T3 cells. J Cancer Res Ther 4: 153–159.

33. Ito H, Funahashi S, Yamauchi N, Shibahara J, Midorikawa Y, et al. (2006) Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin Cancer Res 12: 3257–3264.

34. Lee CH, Fang CY, Shu JH, Chang Y, Takada K, et al. (2008) Amplification on chromosome 3 contains oncogenes induced by recurrent exposure to 12-O-tetradecanoylphorbol-13-acetate and sodium selenite in Balb/c 3T3 cells. J Cancer Res Ther 4: 153–159.
57. Brose K, Tessier-Lavigne M (2000) Slit proteins: key regulators of axon guidance, axonal branching, and cell migration. Curr Opin Neurobiol 10: 95–102.

58. Kidd T, Brose K, Mitchell KJ, Fetter RD, Tessier-Lavigne M, et al. (1998) Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell 92: 205–215.

59. Zallen JA, Yi BA, Bargmann CI (1998) The conserved immunoglobulin superfamily member SAX-3/Robo directs multiple aspects of axon guidance in C. elegans. Cell 92: 217–227.

60. Dickson BJ, Gilestro GF (2006) Regulation of commissural axon pathfinding by slit and its Robo receptors. Anna Rev Cell Dev Biol 22: 651–675.

61. Bhat KM, Gaziouva I, Krishnan S (2007) Regulation of axon guidance by slit and netrin signaling in the Drosophila ventral nerve cord. Genetics 176: 2235–2246.

62. Wu JY, Feng L, Park HT, Hacioglu N, Wen L, et al. (2001) The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature 410: 948–952.

63. Guan H, Zu G, Xie Y, Tang H, Johnson M, et al. (2003) Neuronal repellent Slit2 inhibits dendritic cell migration and the development of immune responses. J Immunol 171: 6519–6526.

64. Prasad A, Qamri Z, Wu J, Ganju RK (2007) Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells. J Leukoc Biol 82: 465–476.

65. Rossi MR, Huntoon K, Cowell JK (2005) Differential expression of the LGI and SLIT families of genes in human cancer cells. Gene 356: 85–90.

66. Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, et al. (2006) Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer 5: 16.

67. Singh RK, Indra D, Mitra S, Mondal RK, Basu PS, et al. (2007) Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet 122: 71–81.

68. Prasad A, Parachuri V, Preet A, Latif F, Ganju RK (2008) Slit-2 induces a tumor-suppressive effect by regulating beta-catenin in breast cancer cells. J Biol Chem 283: 26624–26633.

69. Dalol A, Forgas E, Martinez A, Sekido Y, Walker R, et al. (2002) Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogene 21: 3020–3028.

70. Xian J, Clark KJ, Fordham R, Punnell R, Rabbits TH, et al. (2001) Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene. Proc Natl Acad Sci U S A 98: 15062–15066.

71. Latil A, Chene L, Cochant-Prollet B, Mangin P, Fourrier G, et al. (2003) Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer 103: 306–315.

72. Kuo HK, Zhang H, Li H, Wu TT, Swisher S, et al. (2008) Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma. Neoplasia 10: 1411–1420.

73. Jin J, You H, Yu B, Deng Y, Tang N, et al. (2009) Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun 379: 86–91.

74. Andrews W, Liapi A, Plachez C, Camurri L, Zhang J, et al. (2006) Robo1 regulates the development of major axon tracts and interneuron migration in the forebrain. Development 133: 2245–2252.

75. Liu J, Zhang L, Wang D, Shen H, Jiang M, et al. (2003) Congenital diaphragmatic hernia, kidney agenesis and cardiac defects associated with Slit3 deficiency in mice. Mech Dev 120: 1059–1070.

76. Barik S (2008) An intronic microRNA silences genes that are functionally antagonistic to its host gene. Nucleic Acids Res 36: 5232–5241.